financetom
Business
financetom
/
Business
/
Salesforce Insider Sold Shares Worth $3,514,738, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Salesforce Insider Sold Shares Worth $3,514,738, According to a Recent SEC Filing
Jun 6, 2024 1:38 PM

04:25 PM EDT, 06/06/2024 (MT Newswires) -- Marc Benioff, Director, Chair and CEO, on June 05, 2024, sold 15,000 shares in Salesforce ( CRM ) for $3,514,738. Following the Form 4 filing with the SEC, Benioff has control over a total of 22,347,327 shares of the company, with 12,347,327 shares held directly and 10,000,000 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1108524/000112760224018047/xslF345X03/form4.xml

Price: 242.30, Change: -0.46, Percent Change: -0.19

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China's Huawei Investment plans $10.7 billion in dividends
China's Huawei Investment plans $10.7 billion in dividends
Apr 2, 2024
BEIJING (Reuters) - China's Huawei Investment & Holding Co intends to distribute shareholder dividends amounting to 77.095 billion yuan ($10.65 billion), the Shanghai clearing house said on Tuesday without elaborating. ($1 = 7.2359 Chinese yuan renminbi) ...
Amazon offers free credits for startups to use AI models including Anthropic
Amazon offers free credits for startups to use AI models including Anthropic
Apr 2, 2024
(Reuters) - Amazon Web Service (AWS) has expanded its free credits program for startups to cover the costs of using major AI models, the company told Reuters in an interview, as it looks to boost the market share of its AI platform Bedrock. In a move to attract startup customers, Amazon ( AMZN ) now allows its cloud credits to...
Roivant's anti-inflammatory drug succeeds in mid-stage study
Roivant's anti-inflammatory drug succeeds in mid-stage study
Apr 2, 2024
By Bhanvi Satija April 2 (Reuters) - Roivant Sciences ( ROIV ) said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study. In the study testing 26 patients, 29% of those who received a higher-strength 45 milligram (mg) dose and 44% of those who received a 15 mg...
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
Apr 2, 2024
April 2 (Reuters) - Verve Therapeutics ( VERV ) said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-related adverse event. The company was testing the therapy in patients with a genetic condition that leads to high cholesterol levels, which raises the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved